Asija Sweety, Chatterjee Abhishek, Goda Jayant S, Yadav Sandhya, Chekuri Godhanjali, Purwar Rahul
Department of Biosciences, Indian Institute of Technology, Mumbai, India.
Department of Radiation Oncology, Tata Memorial Centre (TMH & ACTREC) & Homi Bhabha National Institute, Mumbai, India.
Front Immunol. 2023 Mar 15;14:1118246. doi: 10.3389/fimmu.2023.1118246. eCollection 2023.
Glioblastoma is one of the most difficult tumor types to manage, having high morbidity and mortality with available therapies (surgery, radiotherapy and chemotherapy). Immunotherapeutic agents like Oncolytic Viruses (OVs), Immune Checkpoint Inhibitors (ICIs), Chimeric Antigen Receptor (CAR) T cells and Natural Killer (NK) cell therapies are now being extensively used as experimental therapies in the management of glioblastoma. Oncolytic virotherapy is an emerging form of anti-cancer therapy, employing nature's own agents to target and destroy glioma cells. Several oncolytic viruses have demonstrated the ability to infect and lyse glioma cells by inducing apoptosis or triggering an anti-tumor immune response. In this mini-review, we discuss the role of OV therapy (OVT) in malignant gliomas with a special focus on ongoing and completed clinical trials and the ensuing challenges and perspectives thereof in subsequent sections.
胶质母细胞瘤是最难治疗的肿瘤类型之一，现有治疗方法（手术、放疗和化疗）的发病率和死亡率都很高。溶瘤病毒（OVs）、免疫检查点抑制剂（ICIs）、嵌合抗原受体（CAR）T细胞和自然杀伤（NK）细胞疗法等免疫治疗药物目前正被广泛用作胶质母细胞瘤治疗的实验性疗法。溶瘤病毒疗法是一种新兴的抗癌疗法，利用自然界自身的因子来靶向和破坏胶质瘤细胞。几种溶瘤病毒已证明能够通过诱导凋亡或触发抗肿瘤免疫反应来感染和裂解胶质瘤细胞。在本综述中，我们讨论了溶瘤病毒疗法（OVT）在恶性胶质瘤中的作用，特别关注正在进行和已完成的临床试验，以及后续章节中随之而来的挑战和前景。
